Core Viewpoint - Jiangsu Cowin Biotech Co., Ltd. reported a significant increase in revenue for the first half of 2025, with total revenue reaching approximately 87.12 million yuan, a 29.74% increase compared to the same period last year. However, the company also experienced a net loss of approximately 55.91 million yuan, which is an 11.70% increase in losses compared to the previous year [5]. Company Overview - Jiangsu Cowin Biotech Co., Ltd. specializes in molecular detection technology and has over ten years of research and development experience in core technologies related to molecular detection [6]. - The company has developed over 700 core products, including molecular detection raw enzymes, nucleic acid preservation reagents, nucleic acid extraction and purification reagents, and molecular diagnostic kits [6][9]. - The company holds 74 domestic medical device registration or filing certificates and has obtained overseas medical device registrations for 70 products, establishing a comprehensive product system [6]. Financial Performance - For the first half of 2025, the company reported total revenue of 87,118,671.74 yuan, compared to 67,146,615.25 yuan in the same period last year, marking a 29.74% increase [5]. - The total profit for the period was -60,630,052.93 yuan, slightly worse than the -57,766,203.41 yuan reported in the previous year, indicating a 4.96% increase in losses [5]. - The net profit attributable to shareholders was -55,911,138.36 yuan, compared to -50,056,858.08 yuan in the previous year, reflecting an 11.70% increase in losses [5]. Research and Development - The company has established seven technical platforms and 32 core technologies related to molecular detection, and has been granted 33 domestic invention patents and 61 utility model patents [6]. - The company focuses on the research and development of molecular detection raw enzymes, having developed 186 types of enzymes that are widely applicable in various molecular biology experiments [6][9]. Product Development - The company has launched innovative products in the gastrointestinal and respiratory disease screening and diagnosis fields, including a series of nucleic acid detection kits for Helicobacter pylori, which is a significant risk factor for gastric cancer [9]. - The company has developed nucleic acid preservation reagents that are crucial for molecular detection, with over 70 types of products available, ensuring comprehensive sample collection and preservation capabilities [6][9].